One of the biggest stories coming out of Transcatheter Cardiovascular Therapeutics’ annual meeting in Boston this weekend focuses on the success of Edwards Lifesciences Corp.’s freshly FDA-approved ...

Edwards Lifesciences has secured European approval for its transcatheter tricuspid valve replacement system, which the company described as the first minimally invasive therapy of its kind to receive ...

SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...

Abbott Laboratories (ABT) announced on Monday that it has reached an agreement with Edwards Lifesciences Corp. (EW) to settle all outstanding patent disputes related to heart valve medical devices or ...

BOSTON, MA—Patients with significant symptomatic degenerative mitral regurgitation (MR) who had complex anatomy making them ineligible for inclusion in the CLASP IID trial can be treated safely and ...

A device used for the first time in the world by cardiologists at Hillcrest Medical Center’s Oklahoma Heart Institute received authorization by the FDA. The Edwards PASCAL Precision System is used to ...